Loading stock data…
$20.01-0.60 (-2.91%)
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
Precipio, Inc. in the Healthcare sector is trading at $20.01 with a market capitalization of $48M. The stock is currently near its 52-week low of $18.50, remaining 20.4% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.02M↑ | $6.71M↑ | $6.70M↓ | $6.77M↑ | $5.65M |
| Gross Profit | $3.14M↑ | $2.73M↓ | $3.13M↑ | $3.00M↑ | $2.43M |
| Operating Income | -$599,000↑ | -$1.43M↓ | $542,000↑ | -$61,000↑ | -$824,000 |
| Net Income | -$219,000↑ | -$1.44M↓ | $526,000↑ | -$79,000↓ | $74,000 |
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagn...